Novel MRI metrics: Is targeting brain atrophy a practical treatment goal? Yes

Sastre-Garriga J Pareto D Battaglini M , et al. MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nat Rev Neurol 2020; 16(3): 171–182.

Cagol A Schaedelin S Barakovic M , et al. Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis. JAMA Neurol 2022; 79: 682–692.

Zivadinov R Le HH Keenan A , et al. A systematic literature review of the association between global brain atrophy and the Expanded Disability Status Scale score in people with multiple sclerosis. Ther Adv Neurol Disord 2025; 18: 17562864241303681–17562864241303261.

Sormani MP Arnold DL De Stefano N. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol 2014; 75: 43–49.

Sormani MP Schiavetti I Ponzano M , et al. Treatment effect on brain atrophy correlates with treatment effect on cognition in multiple sclerosis. Ann Neurol 2023; 94(5): 925–932.

Cagol A Schaedelin S Pretzsch R , et al. The effect of disease-modifying therapies on brain volume loss and disability accumulation in multiple sclerosis: A systematic review and network meta-analysis. Lancet Reg Health Eur 2025; 59: 101476.

Arnold DL Sprenger T Bar-Or A , et al. Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS. Mult Scler 2022; 28(12): 1927–1936.

Koch M Mostert J Strijbis EM , et al. Breaking the PROMISE: Poor association between brain volume loss and clinical disability worsening over 2 years of follow-up in primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. Epub ahead of print 28 January 2026. DOI: 10.1136/jnnp-2025-337940.

Capanna M Signori A Sormani MP. Is the effect of drugs in progressive MS only due to an effect on inflammation? A subgroup meta-analysis of randomised trials. Mult Scler 2022; 28(11): 1744–1751.

De Stefano N Battaglini M Pareto D , et al. MAGNIMS recommendations for harmonization of MRI data in MS multicenter studies. NeuroImage Clin 2022; 34: 102972.

Kaçar S van Nederpelt DR Jelgerhuis JR , et al. Brain atrophy rates vary with age in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. Epub ahead of print 4 February 2026. DOI: 10.1136/jnnp-2025-337779.

Van Nederpelt DR Bos L Mattiesing RM , et al. Multiple sclerosis-specific reference curves for brain volumes to explain disease severity. Neurology 2025; 104: 1–13.